1 |
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999;281:1623-7.
DOI
|
2 |
Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74.
DOI
|
3 |
Wang D, Yang Y, Zhu J, Li B, Chen J, Yin Y. 3D-conformal RT, fixed-field IMRT and RapidArc, which one is better for esophageal carcinoma treated with elective nodal irradiation. Technol Cancer Res Treat 2011;10:487-94.
DOI
|
4 |
Nicolini G, Ghosh-Laskar S, Shrivastava SK, et al. Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2012;84:553-60.
DOI
|
5 |
Yu WW, Zhu ZF, Fu XL, et al. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol 2014;190:979-86.
DOI
|
6 |
Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012;84:1078-85.
DOI
|
7 |
Koyama S, Tsujii H, Yokota H, et al. Proton beam therapy for patients with esophageal carcinoma. Jpn J Clin Oncol 1994;24:144-53.
|
8 |
Koyama S, Tsujii H. Proton beam therapy with high-dose irradiation for superficial and advanced esophageal carcinomas. Clin Cancer Res 2003;9:3571-7.
|
9 |
Mizumoto M, Sugahara S, Nakayama H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther Onkol 2010;186:482-8.
DOI
|
10 |
Sugahara S, Tokuuye K, Okumura T, et al. Clinical results of proton beam therapy for cancer of the esophagus. Int J Radiat Oncol Biol Phys 2005;61:76-84.
DOI
|
11 |
Zhang X, Zhao KL, Guerrero TM, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. Int J Radiat Oncol Biol Phys 2008;72:278-87.
DOI
|
12 |
Wang J, Wei C, Tucker SL, et al. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2013;86:885-91.
DOI
|
13 |
Shiraishi Y, Xu C, Yang J, Komaki R, Lin SH. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or intensity-modulated radiation therapy. Radiother Oncol 2017;125:48-54.
DOI
|
14 |
Welsh J, Gomez D, Palmer MB, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 2011;81:1336-42.
DOI
|
15 |
Zeng YC, Vyas S, Dang Q, et al. Proton therapy posterior beam approach with pencil beam scanning for esophageal cancer: clinical outcome, dosimetry, and feasibility. Strahlenther Onkol 2016;192:913-21.
DOI
|
16 |
Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 2013;31:183-8.
DOI
|
17 |
Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
DOI
|
18 |
Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-8.
DOI
|
19 |
Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest 2012;30:571-6.
DOI
|
20 |
Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011;17:5473-80.
DOI
|
21 |
Shiraishi Y, Fang P, Xu C, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol 2018;128:154-60.
DOI
|
22 |
Wild AT, Ye X, Ellsworth SG, et al. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 2015;38:259-65.
DOI
|
23 |
MacLennan IC, Kay HE. Analysis of treatment in childhood leukemia: IV. the critical association between dose fractionation and immunosuppression induced by cranial irradiation. Cancer 1978;41:108-11.
DOI
|
24 |
Meyer KK. Radiation-induced lymphocyte-immune deficiency: a factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer. Arch Surg 1970;101:114-21.
DOI
|
25 |
Yoshida T, Inoue H, Usui S, Satodate H, Fukami N, Kudo SE. Narrow- band imaging system with magnifying endoscopy for superficial esophageal lesions. Gastrointest Endosc 2004;59:288-95.
DOI
|
26 |
Makishima H, Ishikawa H, Terunuma T, et al. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis. J Radiat Res 2015;56:568-76.
DOI
|
27 |
Lin SH, Merrell KW, Shen J, et al. Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiother Oncol 2017;123:376-81.
DOI
|
28 |
Kumagai Y, Monma K, Kawada K. Magnifying chromoendoscopy of the esophagus: in-vivo pathological diagnosis using an endocytoscopy system. Endoscopy 2004;36:590-4.
DOI
|
29 |
Yamashina T, Ishihara R, Nagai K, et al. Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma, Am J Gastroenterol 2013;108:544-51.
DOI
|
30 |
Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2012. Esophagus 2019;16:221-45.
DOI
|
31 |
Fujita H, Kakegawa T, Yamana H, et al. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer: comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 1995;222:654-62.
DOI
|
32 |
Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg 1998;175:47-51.
DOI
|
33 |
Shim YM, Kim HK, Kim K. Comparison of survival and recurrence pattern between two-field and three-field lymph node dissections for upper thoracic esophageal squamous cell carcinoma. J Thorac Oncol 2010;5:707-12.
DOI
|
34 |
Booka E, Takeuchi H, Nishi T, et al. The impact of postoperative complications on survivals after esophagectomy for esophageal cancer. Medicine (Baltimore) 2015;94:e1369.
DOI
|
35 |
Nakamura M, Kido Y, Hosoya Y, Yano M, Nagai H, Monden M. Postoperative gastrointestinal dysfunction after 2-field versus 3-field lymph node dissection in patients with esophageal cancer. Surg Today 2007;37:379-82.
DOI
|
36 |
Jiang L, Zhao X, Meng X, Yu J. Involved field irradiation for the treatment of esophageal cancer: is it better than elective nodal irradiation? Cancer Lett 2015;357:69-74.
DOI
|
37 |
Fu WH, Wang LH, Zhou ZM, Dai JR, Hu YM, Zhao LJ. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma. World J Gastroenterol 2004;10:1098-102.
DOI
|
38 |
Yamashita H, Takenaka R, Omori M, et al. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study. Radiat Oncol. 2015 Aug 14;10:171.
DOI
|
39 |
Wang X, Miao C, Chen Z, et al. Can involved-field irradiation replace elective nodal irradiation in chemoradiotherapy for esophageal cancer?: a systematic review and meta-analysis. Onco Targets Ther 2017;10:2087-95.
DOI
|
40 |
Lee DY, Moon SH, Cho KH, et al. Treatment outcomes of extended-field radiation therapy for thoracic superficial esophageal cancer. Radiat Oncol J 2017;35:241-8.
DOI
|
41 |
Welsh JW, Seyedin SN, Allen PK, et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I/II trial. J Thorac Oncol 2017;12:375-82.
DOI
|